JSKN033 not checked
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
4 active
5 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JSKN033 is a fixed-dose combination consisting of JSKN003 (a HER2-targeted ADC) and envafolimab (a PD-L1 inhibitor)”In the company’s words, NCT07283198 on ClinicalTrials.gov
- Tested for
- Recurrent or Metastatic Cervical Cancer, Non Small Cell Lung Cancer (NSCLC), Cervical Cancer, Advanced Malignant Tumors
- Main trialPhase 3
- “This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/L1 inhibitor therapy.”In the company’s words, NCT07797153 on ClinicalTrials.gov
Other drugs for Recurrent or Metastatic Cervical Cancer
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up4
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
- 30 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2028 | JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer | |
| Phase 2Not yet recruiting | 30 Aug 2027 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | |
| Phase 2Not yet recruiting | Oct 2027 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | |
| Phase 1/2Not yet recruiting | 31 Dec 2026 | JSKN033 in Chinese Subjects with Advanced Malignant Tumors | |
| Phase 1/2Terminated | 31 Jul 2025 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026